A Clinical study of safety and P2Y12 receptor inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese patient

Study identifier:D5130C00078

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patients with Coronary Heart Disease: A Randomized, Open Label, Crossover Study

Medical condition

Coronary heart disease

Phase

Phase 3

Healthy volunteers

No

Study drug

90 mg Ticagrelor, 75mg Clopidogrel

Sex

All

Actual Enrollment

0

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Jan 2013
Estimated Primary Completion Date: 01 Apr 2013
Estimated Study Completion Date: 01 Apr 2013

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 May 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria